Vitamin D3 Injection

This product is a vitamin drug. Vitamin D2 promotes the absorption of calcium by the brush border of the small intestinal mucosa and the reabsorption of phosphorus by the renal tubules, increases the concentration of blood calcium and phosphorus, cooperates with parathyroid hormone and calcitonin, promotes the release of calcium phosphate from old bones, and maintains and regulates the normal concentration of plasma calcium and phosphorus. Vitamin D2 promotes the deposition of calcium in the new bone formation site, deposits citrate in the bone, promotes bone calcification and the maturation of osteoblast function and bone-like tissue. After vitamin D2 is ingested, it is catalyzed by the 25-hydroxylase system in the cell microsomes to generate calcidiol (25-OHD3), which is catalyzed by the 1-hydroxylase system of the renal proximal tubular cells to generate biologically active calcitriol [1-25-(OH)2D3].

The main ingredient of this product is vitamin D3.

This product is a light yellow clear oily liquid.

1. For the prevention and treatment of vitamin D deficiency. Such as: absolute vegetarians, patients with parenteral nutrition, pancreatic insufficiency with malabsorption syndrome, hepatobiliary diseases (liver damage, cirrhosis, obstructive jaundice), small intestinal diseases (fatty diarrhea, localized enteritis, long-term diarrhea), gastrectomy, etc. 2. For the treatment of chronic hypocalcemia, hypophosphatemia, rickets and osteomalacia with chronic renal insufficiency, familial hypophosphatemia and hypoparathyroidism (postoperative, idiopathic or pseudohypoparathyroidism). 3. For the treatment of acute, chronic and potential postoperative tetany and idiopathic tetany.

7.5-15 mg (300,000-600,000 units) is injected intramuscularly once. For severe cases, the injection can be repeated after 2-4 weeks.

1. Constipation, diarrhea, persistent headache, loss of appetite, metallic taste in the mouth, nausea and vomiting, thirst, fatigue, and weakness; 2. Bone pain, cloudy urine, convulsions, hypertension, increased eye sensitivity to light stimulation, arrhythmia, occasional mental abnormalities, itchy skin, myalgia, severe abdominal pain (sometimes misdiagnosed as pancreatitis), polyuria at night, and weight loss.

Hypercalcemia, hypervitaminosis D, and hyperphosphatemia with renal rickets.

1. The use of magnesium-containing antacids and vitamin D3 together can cause hypermagnesemia, especially in patients with chronic renal failure. 2. Barbiturates, phenytoin sodium, anticonvulsants, primidone, etc. can reduce the effect of vitamin D3. Therefore, vitamin D3 should be supplemented when taking anticonvulsants for a long time to prevent osteomalacia. 3. The use of calcitonin and vitamin D3 together can offset the efficacy of the former on hypercalcemia. 4. The use of large amounts of calcium or diuretics together with the usual amount of vitamin D3 may cause hypercalcemia. 5. Caution should be exercised when using digitalis and vitamin D3 together, because if vitamin D causes hypercalcemia, it can easily induce arrhythmias. 6. The use of large amounts of phosphorus-containing drugs together with vitamin D3 can induce hyperphosphatemia.

Keep away from light and store in a sealed container.

1 ml: 7.5 mg (300,000 units)

Suzhou Pharmaceutical Factory

• Founded in:

  2006-02-14

• Address:

  No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City

• Tax NO.:

  91320506138170408U

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view